Allon commences Phase II schizophrenia trial and updates clinical progress
Allon Therapeutics Inc. announced that enrolment has commenced in a Phase II clinical trial evaluating Allon's product AL-108 as a treatment for schizophrenia-related cognitive impairment. This study is being conducted in collaboration with TURNS (Treatment Units for Research on Neurocognition and Schizophrenia) and with support from the National Association for Research in schizophrenia and Affective Disorders (NARSAD).
Gordon McCauley, President and CEO of Allon, said the progress is an important next step in determining AL-108's effectiveness in schizophrenia and a broad range of neurological indications. "This third Phase II trial is an important milestone for the Company" McCauley said. "The diversity of our clinical program is an important element to creating shareholder value, exploiting our technology platforms, and certainly helping millions of people suffering from a variety of neurological diseases."
The Phase II trial is a multicenter, double blind, placebo-controlled study, evaluating AL-108 as a potential treatment for cognitive impairment in schizophrenia. The objectives for the trial are to evaluate cognitive impairment using the MATRICS neuropsychological test battery and to assess functional outcome and safety measures. MATRICS is a battery of cognitive tests developed by TURNS to assess cognitive function in schizophrenia patients and is a widely used measure in this area.
Allon and TURNS recently announced an imaging-biomarker component to this trial. Three different imaging techniques will be used to investigate the scope of AL-108 effects in the treatment of schizophrenia and to better understand the impact of AL-108 treatment on brain structure and neural connectivity, both of which are significant to each of Allon's clinical programs.
Other news from the department research and development
